Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of April 2026. The report details a corporate action regarding equity compensation rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the grant of employee warrants.
Material Changes
- Warrant Grant: On April 14, 2026, the Board of Directors granted 32,310 warrants to certain employees.
- Exercise Price: The exercise price is set at US $249.84 per share, based on the closing price of the American Depositary Shares (ADS) on the grant date.
- Vesting Schedule: 25% of the warrants vest on the one-year anniversary of the grant date. The remaining 75% vest monthly at a rate of 1/36th thereafter, subject to continued service.
- Remaining Pool: Following this grant, 1,611,843 warrants remain available for future grant under the Company's Articles of Association.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, outlook, or specific risks. The vesting of warrants is subject to earlier acceleration upon the occurrence of certain exit events.
Investor Verification Checklist
- Verify the impact of the 32,310 new warrants on potential share dilution.
- Confirm the current trading price of ADS relative to the $249.84 exercise price.
- Review the amended Articles of Association (Exhibit 1.1) for specific terms regarding exit event vesting acceleration.
- Check subsequent filings for the next quarterly financial results, as this 6-K does not include them.